74624
document
Dose dependent response of symptoms , pituitary , and bone to transdermal oestrogen in postmenopausal women . The effect of the plasma oestradiol concentration on climacteric symptoms , gonadotrophin release , and bone resorption was studied in three groups of postmenopausal women given 0.025 mg , 0.05 mg , or 0.1 mg transdermal oestradiol daily . There was a dose related reduction in symptoms , plasma follicle stimulating hormone concentration , and urinary calcium and hydroxyproline excretion . The relation of the response to plasma oestradiol values was similar for each variable with an initial large reduction and little change in response to increases in the plasma oestradiol concentration above 150 pmol/l ( 41 pg/ml ) . Hormone replacement therapy producing an effect equivalent to higher oestradiol concentrations is likely to increase the risk of side effects without conferring any additional benefit .
74625
Intervention_Pharmacological
transdermal oestradiol
74626
Intervention_Pharmacological
oestradiol
74627
Outcome_Physical
climacteric symptoms
74628
Outcome_Physical
gonadotrophin release
74629
Outcome_Physical
bone resorption
74630
Outcome_Physical
reduction in symptoms
74631
Outcome_Physical
plasma follicle stimulating hormone concentration
74632
Outcome_Physical
urinary calcium and hydroxyproline excretion
74633
Outcome_Physical
relation of the response to plasma oestradiol values
74634
Outcome_Adverse-effects
side effects
74635
Outcome_Other
additional benefit
74636
Participant_Condition
postmenopausal women .